echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > CanSino Bio-Inhalation Recombinant Novel Coronavirus Vaccine Obtained Clinical Approval

    CanSino Bio-Inhalation Recombinant Novel Coronavirus Vaccine Obtained Clinical Approval

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 23, CanSino Bio announced on the Hong Kong Stock Exchange that the company cooperated with the Institute of Biological Engineering of the Academy of Military Sciences of the Chinese People’s Liberation Army on March 22 to develop a recombinant new coronavirus vaccine for inhalation (adenovirus type 5).


    It is reported that the vaccine is the first approved adenovirus vector new crown vaccine in China.


    According to relevant media reports, CanSino Bio has previously emphasized that according to the interim data of the global multi-center phase III clinical trial, there has been no serious adverse reaction related to the vaccine.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.